Skip to main content
Clinical Trials/CTRI/2010/091/000245
CTRI/2010/091/000245
Completed
Phase 3

Comparative Evaluation of Efficacy and Safety of Primaquine SR Tablets Vs Primaquine Conventional Tablets in the Prevention of Relapse of Plasmodium Vivax Malaria.

Ipca Laboratories Ltd0 sites360 target enrollmentTBD

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Not specified
Sponsor
Ipca Laboratories Ltd
Enrollment
360
Status
Completed
Last Updated
4 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
4 years ago
Study Type
Interventional

Investigators

Eligibility Criteria

Inclusion Criteria

  • 1\.Male and female patients aged 18 \-65 years.2\.Patients with confirmed cases of P. vivax malaria (asexual forms) by microscopy on a thin and thick blood smear with parasite count of \>/\=1,000/µL of blood.3\.Patients with axillary temperature \>/\= 37\.5 °C and with clinical signs and symptoms of malaria.4\. Patients giving written informed consent to participate in this study.5\.patients willing to undergo folloe\-up for 2\-6 months.

Exclusion Criteria

  • 1\. Patients with Mixed malarial infection.
  • 2\.Patients with body weight 40 kg.
  • 3\.Patients with severe or complicated malaria.
  • 4\.Patients with glucose 6\-phosphate dehydrogenase deficiency.
  • 5\.Patients with a history of dark urine or significant hemoglobinuria related to Primaquine treatment during the course of a pervious episode of malaria.
  • 6\.Patient with known history of methomoglobinemia.
  • 7\.Patients taking cardioactive drug or potentially hemolytic drugs.
  • 8\.Patients with concomitant illness (cardiac, hepatic or renal diseases\-blood urea nitrogen (BUN) 20mg/dl or blood urea 40mg/dl, hepatic SGPT or SGOT 2\.5 x ULN, serum bilirubin 2mg/dl and serum creatinine 1\.5mg/dl)).
  • 9\. Patients previously treated with any other antimalarial therapy except chloroquine.
  • 10\.Patients showing any significant abnormality (clinical or laboratory) on pre\-trial screening in the opinion of the investigator.

Outcomes

Primary Outcomes

Not specified

Similar Trials